VDYNE, a privately held medical device company developing technologies for the treatment of tricuspid regurgitation, has secured $21 million in Series C financing.
The financing round was supported by existing investors, including Jean Boulle Medtech, as well as global medical device company.
VDYNE’s technology addresses tricuspid valve regurgitation, a condition whereby the heart can become enlarged due to impaired functionality of the tricuspid valve. The right ventricle’s primary responsibility is to pump blood from the heart to the lungs for re-oxygenation, and eventual recirculation to the body. However, if the tricuspid valve does not close properly during ventricle contraction, then blood flows back or “leaks” from the right ventricle into the right atrium leading to shortness of breath, fatigue, abnormal heart performance and a potentially enlarged heart.
VDYNE’s novel valve replacement and minimally invasive delivery system enables the treatment of a broad range of tricuspid anatomies. VDYNE’s system delivers a prosthetic valve via a transfemoral catheter and is completely repositionable and retrievable. The company is nearing completion of requisite pre-clinical studies and the proceeds from the financing will support first-in-human feasibility studies which are expected to commence in the first half 2021.
Jean Raymond Boulle II, director of both VDYNE and Jean Boulle MedTech, said: “The financing is a significant milestone for VDYNE and we warmly welcome a large, global medical device company to our investor base. We are moving very quickly in our pre-clinical efforts and are looking forward to the commencement of human feasibility studies in the new year.”
